| Zdroj: |
Biotech Week; 7/7/2004, p289-290, 2p |
| Abstrakt: |
Reports on the results from TEMPO (trial of etanercept and methoxerate with radiographic patient outcomes demonstrated that Enbrel (etanercept) therapy allowed significantly more rheumatid arthritis (RA) patients to achieve clinical remission at 2 years compared to patients treated with methotrexate alone. Presentation of the result during the European League Against Rheumatism annual European Congress of Rheumatology in Berlin, Germany; Description of enbrel; tolerance level of the treatment of Enbrel and combination therapy. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
